首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
马士英  赵陆为 《蛇志》1993,5(3):29-29,19
我院采用蝮蛇抗栓酶治疗心房纤颤6例,结果阵发性房颤3例痊愈,持续性房颤3例无效.应用蝮蛇抗栓酶治疗阵发性房颤获得良好效果,原因是蝮蛇抗栓酶有降低血浆纤维蛋白原和血液粘度,改善微循环及扩张冠脉等功能,从而改善心肌和心脏传导系统的血液、氧、能量的供应.恢复心脏的正常功能,消除折返激动而终止房颤.  相似文献   

2.
赵冠群 《蛇志》1994,6(3):28-31
蝮蛇抗栓酶在临床中的新用途赵冠群桂林市医学情报所蝮蛇抗栓酶(Svate,又名清栓酶、去纤酶)是由陆生东北蝮蛇、江浙蝮蛇的蛇毒中提取、分离纯化的蛋白水解酶和精氨酸酶制剂,郝文学等氏业已证实它具有抗凝、溶栓、降脂、去纤、降低血液粘度和血小板聚集、扩张血管...  相似文献   

3.
韦东 《蛇志》1996,(Z1)
蝮蛇抗栓酶临床应用近况(综述)广西中西医结合医院韦东蛇蝮抗栓酶(Svate)是从蝮蛇蛇毒中提取的一种以精氨酸脂酶为主要成分的酶制剂。它具有溶栓、抗凝、去纤、降脂、降低血液粘度、减少血中血栓素B2,增加前列腺素、扩张血管、改善微循环、降低血小板数量、粘...  相似文献   

4.
严惠民  吴蠡荪 《蛇志》1990,2(4):36-37
本文应用蝮蛇抗栓酶(清栓酶)和丹参注射液对高血压、冠心病、脑动脉硬化并有高粘状态84例进行治疗,其中清栓酶组50例;丹参组34例。检测血球压积,全血比粘度、全血还原粘度、血浆比粘度、红细胞电泳、纤维蛋白原、血沉等7项血液流变学指标,并进行治疗前后对比观察。经统计学处理后发现抗栓酶组的治疗效果明显优于丹参组(P<0.005)。抗栓酶有大幅度降低纤维蛋白原的作用。所以蝮蛇抗栓酶是目前应用于血栓病。血液高粘滞血症HVS等病症较为理想的药物。  相似文献   

5.
陆佳华 《蛇志》1995,7(4):48-50
本文报道采用蝮蛇抗栓酶治疗血液粘度异常以上的高粘滞血症47例,以复方丹参对照观察,两组治疗1~2疗程后,复查血液粘度恢复正常者,抗栓酶治疗组占68%,复方丹参治疗组占60%;两种药物对降低全血粘度,血球压积,加快红细胞电泳均有明显作用;抗栓酶对降低纤维蛋白原和男性的全血粘度较复方丹参作用更显著,是治疗高粘滞血症一种较理想的药物,也可作为心脑缺血性血管疾病的预防治疗。  相似文献   

6.
黎达平  刘日兰 《蛇志》1994,6(2):24-30
本文报告了蝮蛇抗栓酶对大鼠实验性矽肺的治疗有很好的疗效。其治疗机理为:通过染尘大鼠肺干重及全肺胶原蛋白测定其T/C值分别为0.68和0.71,其病理切片以1级为主。提示蝮蛇抗栓酶有抑制肺纤维化的作用,延缓矽肺的进展;通过用TBA反应萤光比色法测定肺组织中丙二醛(MDA)含量,结果表明:蝮蛇抗栓酶能显著地降低肺组织中MDA含量(P<0.01)。提示蝮蛇抗栓酶具有体内抗氧化作用,提高体内SOD水平,促进体内抗脂质过氧化的作用。抑制和减慢了肺组织原纤维化过程,从而起到抗胶原反应的作用。同时对抗了矽尘对肺组织损伤作用;通过测定染尘大鼠血液流变学中全血高切和低切粘度比,血浆粘度比、红细胞聚集指数和血沉等指标,均高于正常对照组,说明矽肺存在高粘滞血症,用蝮蛇抗栓酶治疗后其五项指标与矽肺对照组比较有显著性差异(P<0.05)提示蝮蛇抗栓酶有效地改变血液中的高粘滞状态,改善微循环,使矽肺病情得以缓解。  相似文献   

7.
王桂雨  万恩广 《蛇志》1996,8(1):53-54
13例肺心病急性发作期的患者,应用蝮蛇抗栓酶和酚妥拉明治疗,分别在一个疗程开始前和结束后观察心率、PaO2、PaCO2、全血比粘度,血浆比粘度、红细胞压积、纤维蛋白原。其结果是心率减慢、PaO2增高,PaCO2降低,全血比粘度、血浆比粘度、红细胞压积,纤维蛋白原均降低,经t检验P<0.01。症状明显改善,心肺功能好转。文章对蝮蛇抗栓酶和酚妥拉明的作用机理进行了分析和探讨。  相似文献   

8.
蝮蛇抗栓酶治疗周围血管病的护理体会   总被引:1,自引:0,他引:1  
朱卫红 《蛇志》1999,11(1):59-60
蝮蛇抗栓酶是从蝮蛇蛇毒中提取的酶制剂,具有降低血浆纤维蛋白原、降低血液粘稠度和降低血小板聚集功效,是临床上较好的抗血栓药物。我科近年来,以蝮蛇抗栓酶为主治疗33例周围血管病,效果满意,现将护理体会报告如下:1临床资料本组33例中男性21例,女性12例...  相似文献   

9.
李怀中  李成福 《蛇志》1993,5(2):35-35
应用蝮蛇抗栓酶治疗庆大霉素中毒6例,其中1例由于合并严重神经症状及应用蝮蛇抗栓酶时间延长,需8个月治愈,余5例因应用蝮蛇抗栓酶及时,两周即治愈.总之,应用蝮蛇抗栓酶治疗6例庆大霉素中毒患者均获得理想效果。  相似文献   

10.
清栓酶(蝮蛇抗栓酶)的药理研究与临床应用进展   总被引:1,自引:1,他引:0  
清栓酶(蝮蛇抗栓酶)的药理研究与临床应用进展中国蛇协蛇毒研究所邓禄延,覃公平,胡征林自本世纪八十年代起,蛇毒抗凝制剂在我国研制及应用于临床以来,相继有尖吻蝮蛇毒制剂去纤酶,长白山陆生白眉蝮蛇毒制剂清栓酶(蝮蛇抗栓酶)及江浙蝮蛇毒制剂江浙蝮蛇毒抗栓酶(...  相似文献   

11.
Banking on Blood     
  相似文献   

12.
Beside functional and structural changes in vascular biology, alterations in the rheologic properties of blood cells mainly determines to an impaired microvascular blood flow in patients suffering from diabetes mellitus. Recent investigations provide increasing evidence that impaired C-peptide secretion in type 1 diabetic patients might contribute to the development of microvascular complications. C-peptide has been shown to stimulate endothelial NO secretion by activation of the Ca2+ calmodolin regulated enzyme eNOS. NO himself has the potency to increase cGMP levels in smooth muscle cells and to activate Na+ K+ ATPase activity and therefore evolves numerous effects in microvascular regulation. In type 1 diabetic patients, supplementation of C-peptide was shown to improve endothelium dependent vasodilatation in an NO-dependent pathway in different vascular compartments. In addition, it could be shown that C-peptide administration in type 1 diabetic patients, results in a redistribution of skin blood flow by increasing nutritive capillary blood flow in favour to subpapillary blood flow. Impaired Na+ K+ ATPase in another feature of diabetes mellitus in many cell types and is believed to be a pivotal regulator of various cell functions. C-peptide supplementation has been shown to restore Na+ K+ATPase activity in different cell types during in vitro and in vivo investigations. In type 1 diabetic patients, C-peptide supplementation was shown to increase erythrocyte Na+ K+ATPase activity by about 100%. There was found a linear relationship between plasma C-peptide levels and erythrocyte Na+ K+ATPase activity. In small capillaries, microvascular blood flow is increasingly determined by the rheologic properties of erythrocytes. Using laser-diffractoscopie a huge improvement in erythrocyte deformability could be observed after C-peptide administration in erythrocytes of type 1 diabetic patients. Inhibition of the Na+ K+ATPase by Obain completely abolished the effect of C-peptide on erythrocyte deformability. In conclusion, C-peptide improves microvascular function and blood flow in type 1 diabetic patients by interfering with vascular and rheological components of microvascular blood flow.  相似文献   

13.
14.
15.
16.
Cell and Tissue Biology - Besides disease condition, very few stress stimulants were determined to provoke red blood cell (RBC) adhesion to endothelial cells (EC). However, the possible role of...  相似文献   

17.
18.
19.
Stimulated by concerns of potential infective agents in donated blood, commercial enterprises have attempted to develop blood substitutes since the 1900s. After several years of development, a few of the many leads are showing promise. In this article, nanobiotechnological approaches that are now in phase III clinical trials are reviewed, followed by a discussion of how important basic knowledge gained is being used to develop new generations of blood substitutes based on nanobiotechnology.  相似文献   

20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号